|
1
|
Pera M: Trends in incidence and prevalence
of specialized intestinal metaplasia, Barrett’s esophagus, and
adenocarcinoma of the gastroesophageal junction. World J Surg.
27:999–1008. 2003. View Article : Google Scholar
|
|
2
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar
|
|
3
|
Lagergren J and Lagergren P: Recent
developments in esophageal adenocarcinoma. CA Cancer J Clin.
63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edgren G, Adami HO, Weiderpass E and Nyrén
O: A global assessment of the oesophageal adenocarcinoma epidemic.
Gut. 62:1406–1414. 2013. View Article : Google Scholar
|
|
5
|
Hur C, Miller M, Kong CY, Dowling EC,
Nattinger KJ, Dunn M and Feuer EJ: Trends in esophageal
adenocarcinoma incidence and mortality. Cancer. 119:1149–1158.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoyo C, Cook MB, Kamangar F, Freedman ND,
Whiteman DC, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, et al:
Body mass index in relation to oesophageal and oesophagogastric
junction adenocarcinomas: a pooled analysis from the International
BEACON Consortium. Int J Epidemiol. 41:1706–1718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cossentino MJ and Wong RK: Barrett’s
esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest
Dis. 14:128–135. 2003.PubMed/NCBI
|
|
8
|
Spechler SJ, Sharma P, Souza RF, Inadomi
JM and Shaheen NJ; American Gastroenterological Association.
American Gastroenterological Association technical review on the
management of Barrett’s esophagus. Gastroenterology. 140:e18–e52.
2011. View Article : Google Scholar
|
|
9
|
Rubenstein JH and Taylor JB:
Meta-analysis: the association of oesophageal adenocarcinoma with
symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther.
32:1222–1227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baselga J, Carbonell X, Castañeda-Soto NJ,
Clemens M, Green M, Harvey V, Morales S, Barton C and Ghahramani P:
Phase II study of efficacy, safety, and pharmacokinetics of
trastuzumab monotherapy administered on a 3-weekly schedule. J Clin
Oncol. 23:2162–2171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gowryshankar A, Nagaraja V and Eslick GD:
HER2 status in Barrett’s esophagus & esophageal cancer: a
meta-analysis. J Gastrointest Oncol. 5:25–35. 2014.PubMed/NCBI
|
|
14
|
Bang YJ, van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherr CJ and McCormick F: The RB and p53
pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rocco JW and Sidransky D:
p16(MTS-1/CDKN2/INK4a) in Cancer Progression. Exp Cell Res.
264:42–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vieth M, Schneider-Stock R, Rohrich K, May
A, Ell C, Markwarth A, Roessner A, Stolte M and Tannapfel A:
INK4a-ARF alterations in Barrett’s epithelium, intraepithelial
neoplasia and Barrett’s adenocarcinoma. Virchows Arch. 445:135–141.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hardiea LJ, Darnton SJ, Wallis YL, Chauhan
A, Hainaut P, Wilda CP and Cassond AG: p16 expression in Barrett’s
esophagus and esophageal adenocarcinoma: association with genetic
and epigenetic alterations. Cancer Lett. 217:221–230. 2005.
View Article : Google Scholar
|
|
19
|
Wong DJ, Paulson TG, Prevo LJ, Galipeau
PC, Longton G, Blount PL and Reid BJ: p16INK4a lesions
are common, early abnormalities that undergo clonal expansion in
Barrett’s metaplastic epithelium. Cancer Res. 61:8284–8289.
2001.PubMed/NCBI
|
|
20
|
Wang JS, Guo M, Montgomery EA, Thompson
RE, Cosby H, Hicks L, Wang S, Herman JG and Canto MI: DNA promoter
hypermethylation of p16 and APC predicts neoplastic progression in
Barrett’s esophagus. Am J Gastroenterol. 104:2153–2160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaune KM, Neumann C, Hallermann C, Haller
F, Schön MP and Middel P: Simultaneous aberrations of single CDKN2A
network components and a high Rb phosphorylation status can
differentiate subgroups of primary cutaneous B-cell lymphomas. Exp
Dermatol. 20:331–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan J, Knorr J, Altmannsberger M,
Goeckenjan G, Ahr A, Scharl A and Strebhardt K: Expression of p16
and lack of pRB in primary small cell lung cancer. J Pathol.
189:358–362. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harada H, Nakagawa H, Oyama K, Takaoka M,
Andl CD, Jacobmeier B, von Werder A, Enders GH, Opitz OG and Rustgi
AK: Telomerase induces immortalization of human esophageal
keratinocytes without p16INK4a inactivation. Mol Cancer Res.
1:729–738. 2003.PubMed/NCBI
|
|
24
|
Rygiel AM, van Baal JW, Milano F, Wang KK,
Ten Kate FJ, Fockens P, Rosmolen WD, Bergman JJ, Peppelenbosch MP
and Krishnadath KK: Efficient automated assessment of genetic
abnormalities detected by fluorescence in situ hybridization on
brush cytology in a Barrett esophagus surveillance population.
Cancer. 109:1980–1988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gu Y, Rosenblatt J and Morgan DO: Cell
cycle regulation of CDK2 activity by phosphorylation of Thr160 and
Tyr15. EMBO J. 11:3995–4005. 1992.PubMed/NCBI
|
|
26
|
Hong J, Resnick M, Behar J, Wang LJ, Wands
J, DeLellis RA, Souza RF, Spechler SJ and Cao W: Acid-induced p16
hypermethylation contributes to development of esophageal
adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol
Gastrointest Liver Physiol. 299:G697–G706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalinina T, Bockhorn M, Kaifi JT,
Thieltges S, Güngör C, Effenberger KE, Strelow A, Reichelt U,
Sauter G, Pantel K, et al: Insulin-like growth factor-1 receptor as
a novel prognostic marker and its implication as a cotarget in the
treatment of human adenocarcinoma of the esophagus. Int J Cancer.
127:1931–1940. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hector A, Montgomery EA, Karikari C, Canto
M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK,
et al: The Axl receptor tyrosine kinase is an adverse prognostic
factor and a therapeutic target in esophageal adenocarcinoma.
Cancer Biol Ther. 10:1009–1018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Poehlmann A, Kuester D, Malfertheiner P,
Guenther T and Roessner A: Inflammation and Barrett’s
carcinogenesis. Pathol Res Pract. 208:269–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lao-Sirieix P and Fitzgerald RC: Role of
the micro-environment in Barrett’s carcinogenesis. Biochem Soc
Trans. 38:327–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abdel-Latif MM, Duggan S, Reynolds JV and
Kelleher D: Inflammation and esophageal carcinogenesis. Curr Opin
Pharmacol. 9:396–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zarkowska T and Mittnacht S: Differential
phosphorylation of the retinoblastoma protein by G1/S
cyclin-dependent kinases. J Biol Chem. 272:12738–12746. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kitagawa M, Higashi H, Jung HK,
Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E,
Nishimura S, et al: The consensus motif for phosphorylation by
cyclin D1-Cdk4 is different from that for phosphorylation by cyclin
A/E-Cdk2. EMBO J. 15:7060–7069. 1996.PubMed/NCBI
|
|
34
|
Connell-Crowley L, Harper JW and Goodrich
DW: Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell
cycle arrest by site-specific phosphorylation. Mol Biol Cell.
8:287–301. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dick FA: Structure-function analysis of
the retinoblastoma tumor suppressor protein - is the whole a sum of
its parts? Cell Div. 2:262007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rubin SM, Gall AL, Zheng N and Pavletich
NP: Structure of the Rb C-terminal domain bound to E2F1-DP1: a
mechanism for phosphorylation-induced E2F release. Cell.
123:1093–1106. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burke JR, Deshong AJ, Pelton JG and Rubin
SM: Phosphorylation-induced conformational changes in the
retinoblastoma protein inhibit E2F transactivation domain binding.
J Biol Chem. 285:16286–16293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heilmann AM1 and Dyson NJ: Phosphorylation
puts the pRb tumor suppressor into shape. Genes Dev. 26:1128–1130.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song S, Krishnan K, Liu K and Bresalier
RS: Polyphenon E inhibits the growth of human Barrett’s and
aerodigestive adenocarcinoma cells by suppressing cyclin D1
expression. Clin Cancer Res. 15:622–631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lechpammer M, Xu X, Ellis FH,
Bhattacharaya N, Shapiro GI and Loda M: Flavopiridol reduces
malignant transformation of the esophageal mucosa in p27 knockout
mice. Oncogene. 24:1683–1688. 2005. View Article : Google Scholar : PubMed/NCBI
|
